A new study published in JAMA Network Open cautions that prioritizing blood-based colorectal cancer (CRC) screening tests over stool-based tests in federally qualified health care centers (FQHCs) may lead to higher costs and worse outcomes. Using a microsimulation model to evaluate a simulated population with low adherence to screening steps, the researchers found that annual fecal immunochemical testing (FIT) was the most effective and cost-efficient strategy, delivering significantly more life-years gained than triennial blood tests, even with improved adherence to blood testing.
Keep Reading
Add A Comment